Rose Raizman1, Rosemary Hill, Kevin Woo. 1. Rose Raizman, RN-EC, NSWOC, MSc, is nurse practitioner and enterostomal therapist, Centenary Hospital, Toronto, Ontario, Canada. Rosemary Hill, RN, CWOCN, CETN(C), is Certified Wound Ostomy Continence Clinician, Lions Gate Hospital, North Vancouver, British Columbia; Kevin Woo, PhD, RN, NSWOC, WOCC(C), FAPWCA, is Associate Professor, Queens University, Kingston, Ontario. Acknowledgments: Aroa Biosurgery Limited (New Zealand) provided study products, editorial assistance, and travel grants for conference attendance to the authors. Endoform is currently available in the following countries: New Zealand, Canada, US, Germany, Thailand, Jordan, and Mexico. The authors have disclosed no other financial relationships related to this article. Submitted December 20, 2019; accepted in revised form February 19, 2020.
Abstract
OBJECTIVE: To evaluate an advanced extracellular matrix made of ovine forestomach matrix (OFM) for healing a variety of wound types. METHODS: Participants were enrolled from inpatient, outpatient, and home healthcare settings. The OFM was used to treat all wounds and applied to the wound bed every 3 to 7 days until closure. RESULTS: Researchers enrolled 29 participants with 33 wounds. Average time to wound closure was 8.2 weeks, the percentage of wounds that reduced in size by 50% or more at 4 weeks was 64%, the average wound area reduction at 4 weeks was 66%, and 73% of wounds had closed at 12 weeks. No adverse effects were observed. CONCLUSIONS: This represents the first Canadian evaluation of OFM for the treatment of wounds, and the positive healing outcomes observed could support more widespread adoption of this matrix.
OBJECTIVE: To evaluate an advanced extracellular matrix made of ovine forestomach matrix (OFM) for healing a variety of wound types. METHODS:Participants were enrolled from inpatient, outpatient, and home healthcare settings. The OFM was used to treat all wounds and applied to the wound bed every 3 to 7 days until closure. RESULTS: Researchers enrolled 29 participants with 33 wounds. Average time to wound closure was 8.2 weeks, the percentage of wounds that reduced in size by 50% or more at 4 weeks was 64%, the average wound area reduction at 4 weeks was 66%, and 73% of wounds had closed at 12 weeks. No adverse effects were observed. CONCLUSIONS: This represents the first Canadian evaluation of OFM for the treatment of wounds, and the positive healing outcomes observed could support more widespread adoption of this matrix.
Authors: Brandon A Bosque; Christopher Frampton; Abigail E Chaffin; Gregory A Bohn; Kevin Woo; Candace DeLeonardis; Brian D Lepow; M Mark Melin; Tobe Madu; Shane G Dowling; Barnaby C H May Journal: Int Wound J Date: 2021-08-06 Impact factor: 3.099
Authors: Matthew J Smith; Sandi G Dempsey; Robert Wf Veale; Claudia G Duston-Fursman; Chloe A F Rayner; Chettha Javanapong; Dane Gerneke; Shane G Dowling; Brandon A Bosque; Tanvi Karnik; Michael J Jerram; Arun Nagarajan; Ravinder Rajam; Alister Jowsey; Samuel Cutajar; Isaac Mason; Roderick G Stanley; Andrew Campbell; Jenny Malmstrom; Chris H Miller; Barnaby C H May Journal: J Biomater Appl Date: 2021-11-07 Impact factor: 2.646